A previous study of the anti-EGFR Nanofitin showed high tumor specificity in vivo, with significant accumulation in EGFR-expressing tumors and minimal accumulation in non-EGFR-expressing tumors or healthy organs (heart, lungs, skin) 2.5 h post-injection [16]. This evidence concerns the gene EGFR and neoplasm.